Leukemic stem cells and therapy resistance in acute myeloid leukemia

A major obstacle in the treatment of acute myeloid leukemia (AML) is refractory disease or relapse after achieving remission. The latter arises from a few therapy-resistant cells within minimal residual disease (MRD). Resistant cells with long-term self-renewal capacity that drive clonal outgrowth a...

Descripción completa

Detalles Bibliográficos
Autores principales: Stelmach, Patrick, Trumpp, Andreas
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Fondazione Ferrata Storti 2023
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9890038/
https://www.ncbi.nlm.nih.gov/pubmed/36722405
http://dx.doi.org/10.3324/haematol.2022.280800

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9890038/
https://www.ncbi.nlm.nih.gov/pubmed/36722405
http://dx.doi.org/10.3324/haematol.2022.280800

Ejemplares similares